Understanding how cells silence harmful genetic elements
Epigenetic Mechanisms of Retrotransposon Silencing
['FUNDING_OTHER'] · VAN ANDEL RESEARCH INSTITUTE · NIH-10928090
This study is looking at how our cells keep certain genetic elements, which can cause problems if they become active, turned off, and it aims to find new ways to help treat diseases that might be caused by these elements getting switched on.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VAN ANDEL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (GRAND RAPIDS, UNITED STATES) |
| Trial ID | NIH-10928090 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which cells silence retrotransposons, which are genetic elements that can disrupt cell function and viability if activated. The study focuses on the role of specific proteins and epigenetic modifications that help keep these elements inactive, thereby preventing potential damage to the genome. By exploring the molecular processes involved in retrotransposon silencing, the research aims to uncover insights that could lead to new therapeutic strategies for diseases linked to their activation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with genetic disorders or cancers where retrotransposon activation is implicated.
Not a fit: Patients with conditions unrelated to retrotransposon activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for diseases caused by the activation of retrotransposons, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding epigenetic mechanisms, suggesting that this approach could yield valuable insights.
Where this research is happening
GRAND RAPIDS, UNITED STATES
- VAN ANDEL RESEARCH INSTITUTE — GRAND RAPIDS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WORDEN, EVAN J — VAN ANDEL RESEARCH INSTITUTE
- Study coordinator: WORDEN, EVAN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers